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Abstract. Brain-derived neurotrophic factor (BDNF) has been 
observed to be elevated in solid tumors including colorectal 
cancer. The present study aimed to investigate the effect of 
modulation of BDNF at the transcription level on the cellular 
function of colorectal cells and to increase our understanding 
of its biological role in human colon cancer. An investigation 
of a cohort of human colorectal tissues (tumor n=66; normal 
n=88) using quantitative PCR and immunohistochemistry 
demonstrated that BDNF is aberrantly expressed in human 
colon cancer and a significantly raised level of BDNF is 
associated with its stage at diagnosis. The expression profile of 
BDNF in human colon cancer cell lines was evaluated using 
RT-PCR. A set of anti-BDNF ribozymes were used to transfect 
colon cancer cells in order to generate BDNF knockdown cells 
to evaluate the effect on growth and apoptosis. BDNF gene 
transcripts were successfully detected in the colon cancer cell 
lines, Caco-2 and HRT18. BDNF knockdown in Caco-2 and 
HRT18 cell lines resulted in decreased rates of growth and 
proliferation. Analysis of apoptosis showed that cell apoptosis 
was increased. It is concluded that BDNF, a neurotrophic 
growth factor aberrantly expressed in cancers such as colon 
cancer, has a profound impact on the cellular behavior of colon 
cancer cells and that BDNF is associated with a reduction in 
the apoptosis of colon cancer. BDNF is therefore a potential 
therapeutic target in colon cancer and its effect in human colon 
cancer requires further investigation.
Introduction
Colon cancer is one of the most common gastrointestinal 
sarcomas. The incidence of colon cancer in North America and 
Western Europe is higher than that in developing countries, 
but there is also a trend to increasing incidences in developing 
countries (1,2). The etiology of colon cancer remains unclear, 
but is believed to be closely associated with environmental 
factors, genetic factors and pre-cancerous diseases. The 
survival rate of patients with colon cancer is closely associated 
with the stage of the disease, early diagnosis and treatment, 
which would also contribute to improvement in survival and 
prognostic evaluation. The treatment of colon cancer includes 
surgery, chemotherapy, radiotherapy, immunotherapy and 
biotherapy. Due to its molecular and cellular diversification, the 
individual treatment of colon cancer has attracted much atten-
tion. In addition, >25% of colon cancer cases occur in patients 
with a family history of colon cancer. Prevention, monitoring 
or preventive treatment of individuals at high risk has become 
extremely important (3,4). The discovery of new colon cancer 
tumor markers and the mechanism underlying their modality 
may provide new targets for diagnosis and treatment.
The expression level and impact of brain-derived neuro-
trophic factor (BDNF) has been reported in several types 
of carcinomas, although how this protein exerts its effects 
remains to be identified (5). BDNF is a protein composed of 
247 amino acids, which was initially separated and purified 
from pig brain (6). It is a member of the nerve growth factor 
family and is secreted by the target cells for BDNF, being 
important to the phenotypic behavior of neurons or neural 
system cancers. BDNF mediates cellular biological effects 
mainly through a cell surface tyrosine kinase receptor, tropo-
myosin-related kinase B (TrkB). The extracellular N-terminal 
binds to BDNF, followed by receptor autophosphorylation to 
activate signaling pathways in cells (7).
In previous years it has been shown that BDNF expression 
is associated with different functions in non-neuronal solid 
tumors. BDNF expression controls cellular proliferation and 
survival, and is also connected to cell invasion via the secre-
tion of matrix metalloproteinase (8-12). The PI3K/AKT and 
ERK pathways in tumor cells activated by BDNF may result in 
cells that are not sensitive to chemotherapeutic drugs (13,14). 
As previously reported, screening of clinical samples has 
revealed that BDNF is highly expressed in colon carcinoma 
compared with non-tumor tissues (5). The present study 
aimed to investigate the biological roles of BDNF expression 
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in human colon cancer. We investigated the expression level 
and the impact of BDNF in clinical samples. We observed 
high expression of BDNF in Caco-2, HRT18 and RKO human 
colon cancer cells and therefore anti-BDNF ribozymes were 
constructed to knock down the expression of BDNF in these 
cell lines. We then investigated the effects of BDNF knock-
down on cellular behavior.
Materials and methods
Patient samples. Colorectal cancer tissues (n=66) and normal 
background tissues (n=88) were collected immediately after 
surgery and stored in a deep freeze until use. The presence of 
tumor cells in the collection tissues was verified by a consultant 
pathologist following hematoxylin and eosin (H&E) staining 
of the frozen sections. Details of the histology were obtained 
from pathology reports and together with basic patient demo-
graphics are shown in Tables I and II. The anonymous breast 
tissue samples were obtained within the guidelines of the 
appropriate ethics committee [University Hospital of Wales 
Trust (05/DMD/3562)]. informed patient consent was obtained 
following guidelines set out by the Human Tissue Act 2004, 
UK (http://www.legislation.gov.uk/ukpga/2004/30/contents).
RNA preparation and reverse transcription PCR (RT-PCR). 
Total cellular RNA was extracted from the cultured cells 
using Total RNA Isolation reagent (ABgene, Epsom, UK). The 
concentration of RNA was determined using an ultraviolet 
spectrophotometer (WPA UV 1101; Biotech Photometer, 
Cambridge, UK). cDNA was obtained by RT-PCR using a 
transcription kit (Sigma, Poole, UK). The quality of DNA was 
verified using GAPDH primers. The mRNA levels of BDNF 
were assessed using the BDNF primers. PCR were run on a 
GeneAmp PCR System 2400 thermocycler (Perkin-Elmer, 
Waltham, MA, USA). The PCR products were separated by 
1% agarose gel, stained with ethidium bromide and images 
were captured with a digital camera mounted over a UV trans-
luminator.
Quantitative PCR (qPCR). The mRNA level of BDNF gene 
expression was determined by the qPCR method using the 
prepared cDNA as the template and BDNF primers. An 
additional primer sequence was added to every qPCR system, 
known as the Z sequence (5'-ACT GAA CCT GAC CGT 
ACA-3'), which is complementary to the universal Z probe 
(Intergen Inc., Oxford, UK). The reaction was carried out in an 
IcyclerIQ™ (Bio-Rad, Hemel Hemstead, UK) using 96-well 
plates. GAPDH expression was used as an internal control. The 
reaction conditions were as follows: 94˚C for 7 min, 80 cycles 
of 94˚C for 15 sec, 55˚C for 35 sec (the data capture step) and 
72˚C for 20 sec. The levels of the transcripts were generated 
from an internal standard that was simultaneously amplified 
with the samples.
Immunohistochemistry of clinical samples. Cryostat sections 
of frozen tissues were cut at 6 µm, placed on Super Frost 
Plus slides (LSL UK, Rochdale, UK), air dried and fixed in 
a 50:50 solution of alcohol:acetone. The sections were then 
air dried again and stored at -20˚C until used. Immediately 
prior to immunostaining, the sections were washed in 
buffered saline solution (BSS) for 5 min and treated with 
horse serum (Sigma-Aldrich Co. Ltd., Gillingham, UK) 
for 20 min as a blocking agent to non-specific binding. 
The sections were stained using BDNF antibody (Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Negative 
controls were used where necessary. The primary antibody 
was used at 1:100 dilution for 60 min and the sections were 
washed in buffer. The secondary biotinylated antibody 
at 1:100 dilution (Universal secondary, Vectastain Elite 
ABC; Vector Laboratories Inc., Burlingame, CA, USA) was 
added (in horse serum/buffer solution) for 30 min, followed 
by numerous washings. Avidin/biotin complex (Vector 
Laboratories Ltd., Peterborough, UK) was added for 30 min 
and followed by washes. Diaminobenzidine (Sigma-Aldrich 
Co. Ltd.) was used as a chromogen to visualize the antibody/
antigen complex. Sections were counterstained with Mayer's 
hematoxylin for 1 min, dehydrated, cleared and mounted in 
DPX. 
Cell lines. The human colon cancer cell lines, Caco-2, HRT18 
and RKO were obtained from the European Collection of 
Animal Cell Cultures (ECACC, Salisbury, England). Cells 
were maintained in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% fetal calf serum, 100 U/ml peni-
cillin and 100 µg/ml streptomycin (Gibco BRC, Paisley, UK) 
at 37˚C and 5% CO2.
Knockdown of BDNF expression using ribozyme and 
screening of stable transfected cell line. Ribozymes targeted 
to human BDNF transcription levels were designed based on 
the secondary structure of the gene generated using the Zuker 
RNA mFold program (University of Albany, New York, NY, 
USA). The ribozymes were accordingly synthesized and then 
cloned into pEF6/V5-his-Topo T/A vector (Invitrogen, Paisley, 
UK) and transfected into Caco-2 and HRT18 cells using an 
Easyjet Plus electroporator (EquiBio, Kent, UK). Following 
selection with culture medium containing 5 µg/ml blasticidin 
(Sigma-Aldrich Co. Ltd.), the verified transfectants were 
cultured in maintenance medium containing 0.5 µg/ml blas-
ticidin. The primer sequences of the BDNF ribozymes were 
as follows: 5'-CTG CAG TTG GCC TTT TGA TAC AGG 
GAC CTT TTC AAG GAC TGT CTG ATG AGT CCG TGA 
GGA-3' and 5'-ACT AGT GCA GTG GAC ATG TCG GGC 
GGG ACG GTT TCG TCC TCA CGG ACT-3'.
Cell growth assay. Colon cancer cell growth rates were 
assessed using an in vitro growth assay. Cells were planted 
in sextuplicate into 96-well plates at a density of 2,000 cells 
per well. The plates were then incubated for 24, 48, 72 and 
120 h before being fixed in 4% formaldehyde (v/v) and stained 
with 0.5% (w/v) crystal violet. The crystal violet stain was 
then extracted using 10% acetic acid (v/v) and cell density was 
determined by measuring the absorbance of this solution at 
540 nm using a Bio-Tek ELx800 multi-plate reader (Bio-Tek 
Instruments Inc., Winooski, VT, USA).
Flow cytometric analysis of apoptosis. All cells, including 
those floating in the culture medium, were harvested following 
incubation. Cells were washed in cold BSS and resuspended in 
1X annexin V- binding buffer at a density of 1x106 cells/ml after 
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centrifugation for 8 min at 13,000 x g. Fluorescein isothiocya-
nate (FITC)-annexin V (5 µl) and 1 µl propidium iodide (PI) 
working solution (100 µg/ml; Molecular Probes, Eugene, OR, 
USA) were added to 100 µl cell suspension. After a 15-min 
incubation at room temperature, 400 µl 1X annexin V-binding 
buffer was added and mixed in gently, and the samples were 
immediately kept on ice. The stained cells were analyzed 
using a flow cytometer and FlowMax software (Partec UK 
Ltd., Canterbury, UK). 
Statistical analysis. Statistical analysis was performed using 
SPSS software (SPSS, Inc., Chicago, IL, USA). P<0.05 was 
considered to indicate a statistically significant result.
Results
Expression of BDNF in human colon cancer. BDNF was 
observed to be expressed in colon cancer tissues and normal 
tissues. BDNF mRNA expression levels were detected using 
qPCR. Significantly higher mRNA levels were observed in 
colon cancer tissues compared with normal tissues (P=0.017; 
Fig. 1A). BDNF expression was significantly increased with 
increasing differentiation of colorectal tumors (well differenti-
ated tumors versus moderate/poorly differentiated, P=0.017; 
Fig. 1B) and also increased with increasing T-staging (T-stage 1 
versus 2 and 3, P=0.037; Fig. 1C). Patients who succumbed to 
colorectal cancer also had elevated levels of BDNF, P=0.055, 
but this did not reach significance (Fig. 1D). BDNF was also 
increased with Dukes staging [normal (2312±171) versus 
Dukes A 314±195, P=0.031; normal versus Dukes B and C 
(3276+/-1326), P=0.025]. Immunohistochemical staining 
showed only a small increase in BDNF protein in tumor 
tissues, compared with that in normal background colorectal 
tissues (Fig. 1E).
mRNA expression of BDNF in human colon cancer cell lines. 
Human cancer cell lines Caco-2, HRT18 and RKO were 
examined for the presence of BDNF using RT-PCR (Fig. 2A). 
Table I. Median values of BDNF expression in patient samples.
Clinical/pathological features Sample (No.) Median Q1-Q3 P-value
Normal 68 0 0-7 
Tumor 88 25.5 2-438 <0.0001
Paired N  58 0 0-9.4 
Paired T  64 13 1-261 0
TNM    
  Normal 68 0 0-7 
  TNM1   9 163.4 39-1545 0.0001
  TNM2 27 11 1-458 <0.0001
  TNM3 25 7 1-175 0.0006
  TNM4   6 244 1-939 0.0095
  TNM2&3 52 10 1-246 0.0934
T1234    
  Normal 68 0 0-7 
  T-1   2 1491 NC 0.1435
  T2   9 451 66-9953 <0.0001
  T3 37 5 0-107 0.0001
  T4 18 53 6-1058 <0.0001
  T2   9 451 66-9953 
  T3 37 5 0-107 0.0033
  T2   9 451 66-9953 
  T3&4 55 11 1-261 0.0086
Duke    
  Normal 68 0 0-7 
  Dukes A   7 74 20-451 0.0012
  Dukes B 30 13 2-610 <0.0001
  Dukes C 31 11 1-458 0.0001
  Dukes BC 61 11 1-481 <0.0001
Alive 33 7 0-175 
Deceased 22 82 7-744 0.0554
BDNF, brain-derived neurotrophic factor. NC, not calculated.
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BDNF was strongly expressed in all three cell lines. Fetal 
kidney tissue was used as a positive control. The negative 
control had no DNA template (data not shown).
BDNF knockdown and establishment of stable cell lines. The 
ribozymes targeting BDNF were cloned into pEF6/V5-his-Topo 
T/A vector. Caco-2 and HRT18 wild type cells were subjected 
to transfection using plasmids containing ribozymes targeting 
BDNF or an empty vector control, respectively, followed by 
the establishment of BDNF knockdown sub-lines and empty 
vector (pEF) control cells. The expression of BDNF at the 
mRNA level was reduced in BDNF knocked-down HRT18 
and Caco-2 cells using RT-PCR and qPCR (Fig. 2B and C). 
We then characterized the effects of BDNF knockdown in 
these cells through a series of in vitro studies.
Effects of BDNF knockdown on the growth of human colon 
cancer cells. In the in vitro growth assay, knockdown of BDNF 
in Caco-2 and HRT18 cells resulted in a reduction of cell growth 
rate (growth rate in BDNF knocked-down Caco-2 cells by day 3 
Rib=1.24±0.15, compared with 3.15±0.12 in pEF, P=0.0000; 
Fig. 2D). Loss of BDNF in HRT18 cells resulted in reduction of 
cell growth rate (growth rate in BDNF knocked-down HRT18 
cells by day 3 Rib=4.47±0.13, compared with 7.00±0.43 in 
pEF, P=0.0001; Fig. 2E). These data demonstrate that BDNF 
may increase colon cancer cell growth.
Effects of BDNF knockdown on cell apoptosis. To investi-
gate whether apoptosis is involved in the effect of BDNF 
knockdown in Caco-2 and HRT18 cells, we determined the 
proportion of apoptotic cells. As shown in Fig. 3A-D, there 
was an increase in cell population towards apoptosis in the 
BDNF knocked-down Caco-2 and HRT18 cells, which was 
46.19% in the BDNF knocked-down Caco-2 cells, compared 
with 16.86% in the pEF control. There was also an increase 
of apoptosis in the BDNF knocked-down HRT18 cells, which 
was 68.01% in the BDNF knocked-down cells, compared with 
46.63% in the pEF control. These results suggest that BDNF 
decreases apoptosis in these cells.
In addition, we confirmed whether or not this effect was 
specific to BDNF knockdown by rescue experiments. BDNF 
protein was added in the cell culture medium (50 ng/ml) and 
resulted in a negated effect of BDNF knocked-down HRT18 
cells compared with the pEF controls (Fig. 3C and D).
Table II. Mean values of BDNF from patient samples.
Clinical/pathological features Sample (No.) Mean SE Mean P-value
Normal 68 212 171 
Tumor 88 2797 1003 0.013
Paired N 58 50 26 
Paired T 64 2224 887 0.017
Differentation    
  Normal 68 212 171 
  Diff 1 2 47.1 27 0.340
  Diff 2  50 1918 785 0.039
  Diff 3 14 7574 5023 0.170
  Diff 2&3 64 3155 1265 0.024
T1234    
  Normal 68 212 171 
  T-1 2 1491 1491 0.550
  T2 9 9594 7107 0.220
  T3 37 2601 1307 0.078
  T4 18 914 499 0.200
  T2&3 46 3969 1740 0.037
  T3&4 55 2049 896 0.049
  T2&3&4 64 3110 1266 0.027
Normal 68 212 171 
No Invasion 48 1770 931 0.110
Invasive 24 4989 2822 0.100
Disease free 32 4757 2406 0.069
Incidence 23 1874 1021 0.120
Alive  33 3728 2233 0.130
Deceased 22 3219 1559 0.069
BDNF, brain-derived neurotrophic factor.
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Effects of BDNF knockdown on cellular signal pathways. 
We screened the cells at the mRNA transcript level for bcl-2 
in BDNF knocked-down HRT18 cells using qPCR. The 
results showed that the level of bcl-2 was reduced in BDNF 
knockdown HRT18 cells, indicating that BDNF stimulates the 
message for bcl-2. (Fig. 3E).
Discussion
BDNF has been observed to be elevated in non-nervous system 
solid tumors including colorectal cancer. However, the impacts 
of BDNF transcription level on cellular biological function and 
the molecular pathways induced by BDNF are unknown (15). 
Figure 1. BDNF levels in human colorectal tumor tissues. Values represent the true copy number of mRNA transcripts. (A) Levels of BDNF transcript 
between normal and tumor tissues. *Normal vs. tumor. (B) Levels of BDNF transcript in differentiated tumors. *Normal vs. differentiation 2-3. (C) BDNF 
transcript levels and T-staging. *Normal vs. T-Stage 2-4. (D) Levels of BDNF transcript and patient survival. *Normal vs. succumbed to colorectal cancer. 
(E) Representative immunohistochemistry of BDNF protein in colorectal normal/background and tumor tissues. BDNF, brain-derived neurotrophic factor.
Figure 2. BDNF expression in human colon cancer cell lines and cell growth analysis. (A) Detection of BDNF mRNA transcription in Caco-2, HRT18 and 
RKO colon cancer cell lines using RT-PCR. GAPDH was used as the housekeeping control. (B) Knockdown of BDNF expression in Caco-2 cell lines. RT-PCR 
showed BDNF suppression at the mRNA level in Caco-2 cell lines. (C) Knockdown of BDNF expression in HRT18 cell lines. qPCR showed BDNF suppression 
at the mRNA level in HRT18 cell lines. (D) Knockdown of BDNF inhibited the Caco-2 cell growth compared with that of empty vector (pEF) control cells. 
(E) Knockdown of BDNF inhibited HRT18 cell growth compared with the control. **Significantly different, P=0.0001 BDNF, brain-derived neurotrophic factor. 
  A   B   C   D
  E
  A   B
  C   D   E
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In our patient cohort, we found BDNF to have significantly 
elevated levels in tumors with poor prognosis and, to the best 
of our knowledge, this is the first study of its kind.
The expression levels of BDNF and TrkB mRNA have 
been demonstrated to be higher in human cancer cell lines 
than in normal tissues (16). Our results also show that the 
mRNA expression level of BDNF in human colon cancer is 
elevated. Therefore we utilized RNA knockdown experiments 
to study the effects of BDNF expression on cellular function 
and the possible molecular mechanisms. In the present study 
we obtained stable knockdowns of BDNF in human colon 
cancer cell lines using anti-BDNF ribozymes.
When BDNF was stably knocked down in Caco-2 and 
HRT18 cell lines, the growth decreased compared with that 
of cells transfected with the vector control, suggesting that 
reduced BDNF gene expression inhibited cellular proliferation. 
These results indicate that BDNF facilitates the proliferation 
of human colon cancer cells.
The apoptosis experiments demonstrated that in the Caco-2 
and HRT18 cell lines in which BDNF was stably knocked 
down, apoptosis increased compared with that of the cells 
transfected with the vector control. In addition, we observed 
that when BDNF was added the apoptosis increased in HRT18 
cells in which BDNF was stably knocked down. These results 
Figure 3. Effects of BDNF knockdown on cell apoptosis and the Bcl-2 pathway. (A) BDNF knockdown induces apoptosis in Caco-2 cell lines. Apoptosis was 
reduced compared with that of empty vector (pEF) control cells. (B) Statistical analysis of apoptosis. (C) BDNF knockdown induces apoptosis in HRT18 cell 
lines which was reversed using rescue experiments following exposure to BDNF (50 ng/ml) for 48 h. Apoptosis was reduced compared with that in pEF control 
cells. (D) Statistical analysis of apoptosis rescue using BDNF recombinant protein. (E) Effects of BDNF knockdown reduced the mRNA expression level of 
bcl-2 as assessed using RT-PCR. *Significant difference of pEF vs, BDNF ribozyme, P<0.001 BDNF, brain-derived neurotrophic factor.
  A   B
  C
  D   E
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suggest that BDNF is a regulator of apoptosis in these cells. 
We conclude that BDNF is able to maintain colon cancer cell 
survival and proliferation.
The effect of BDNF on cellular biological functions is 
induced mainly by its receptor TrkB. When BDNF binds to 
TrkB the tyrosine kinase activity of the receptor is activated via 
phosphorylation of tyrosine residues in the cytoplasmic region 
of the receptor, which in turn induces cellular signaling (10,17). 
The PI3K-AKT pathway is closely associated with cell 
survival and PI3K plays a key role in anti-apoptotic survival 
and proliferation (9,18,19). BDNF activates the AKT pathway 
in order to maintain cell survival (20). In this study, we 
also investigated the expression of downstream molecules 
associated with the AKT pathway. Bcl-2 as a member of the 
bcl-2 family, negatively regulates cell death and acts as an 
anti-apoptosis factor. Bcl-2 was downregulated in the BDNF 
knocked-down HRT18 cells compared with the level in the 
cells transfected with vector control. Accordingly, BDNF 
induces the increased transcription of bcl-2 to inhibit apop-
tosis and facilitate survival. BDNF downregulation eliminated 
protection from apoptosis, likely via the BDNF-Akt-Bcl2 
anti-apoptotic signaling pathway (19).
In conclusion, our study shows that BDNF facilitates 
cell proliferation and inhibits cell apoptosis in human colon 
cancer cells. Reduced BDNF expression induces changes 
in downstream signaling molecules that are associated with 
cell survival and apoptosis. BDNF is therefore a potential 
therapeutic target in colon cancer and its effect in human colon 
cancer requires further investigation.
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